NetworkNewsBreaks – Grey Cloak Tech Inc. (GRCK)
Post# of 121
Grey Cloak Tech’s (OTC: GRCK) announcements of a planned name change and its new Clinical IMMUNE(tm) product designed to combat respiratory symptoms were top topics in this week’s issue of the “Emerging Markets Report”. The report noted that Grey Cloak Tech recently filed to change its name to Healthy Extracts Inc. to better align with its science-based, exclusive products and intellectual properties. The name change also reflects the company’s focus on its proprietary development of natural plant-based formulations and the sale and distribution of cardiovascular and neuro products. In addition, the company is releasing a new product — Clinical IMMUNE — which “Emerging Markets Report” notes is particularly timely as the COVID-19 pandemic continues and flu season begins. “We are excited to introduce Clinical IMMUNE, a truly unique product among all the immune products available in the market today,” stated Grey Cloak Tech president Duke Pitts, who was quoted in the press release. “Consumers would have to take up to 22 pills a day to accomplish what Clinical IMMUNE does with just two pills. In addition, people could be spending up to $200 a month for the 11 key ingredients contained in Clinical IMMUNE, all for under $40 a month. Clinical IMMUNE is not only designed for today’s conditions but is incredible for enhancing immune defense against flu and colds. We believe Clinical IMMUNE will become part of a daily health routine and one of our largest-selling products for years to come.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer